Acurx Pharmaceuticals Publishes Landmark Study on New Antibiotic Mechanism Targeting Priority Pathogens Acurx Pharmaceuticals unveils groundbreaking research on DNA polymerase IIIC inhibitors, showcasing promising new antibiotics against severe bacterial infections.

Acurx Pharmaceuticals Publishes Landmark Study on New Antibiotic Mechanism Targeting Priority Pathogens #USA #Ibezapolstat #Acurx #Staten_Island #Antibiotics

Acurx's Innovative Research Differentiates Ibezapolstat's Impact on Gut Microbiome Acurx Pharmaceuticals published groundbreaking results showing how Ibezapolstat uniquely affects the gut microbiome, distinguishing it from other antibiotics used for CDI.

Acurx's Innovative Research Differentiates Ibezapolstat's Impact on Gut Microbiome #USA #Ibezapolstat #Acurx #Staten_Island #CDI

Acurx Pharmaceuticals Revels in Positive In-Silico Findings on Ibezapolstat's Efficacy for CDI Treatment Acurx Pharmaceuticals has unveiled promising findings from their in-silico study on ibezapolstat, showcasing its potential to restore gut microbiome in CDI treatment.

Acurx Pharmaceuticals Revels in Positive In-Silico Findings on Ibezapolstat's Efficacy for CDI Treatment #USA #Ibezapolstat #Acurx #Staten_Island #CDI

Acurx Pharmaceuticals Advances Ibezapolstat to Phase 3 Trials for C. Difficile Infections Following Regulatory Endorsements Acurx Pharmaceuticals is gearing up for international Phase 3 clinical trials for its antibiotic Ibezapolstat, targeting C. difficile infections, following positive feedback from the FDA and EMA.

Acurx Pharmaceuticals Advances Ibezapolstat to Phase 3 Trials for C. Difficile Infections Following Regulatory Endorsements #USA #Ibezapolstat #Acurx #C._difficile #Staten_Island